CHRIS AMOS to Ovarian Neoplasms
This is a "connection" page, showing publications CHRIS AMOS has written about Ovarian Neoplasms.
Connection Strength
1.527
-
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers. Mov Disord. 2023 04; 38(4):604-615.
Score: 0.147
-
Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med. 2022 01 11; 20(1):3.
Score: 0.136
-
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer. 2020 02; 122(3):405-412.
Score: 0.117
-
Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
Score: 0.111
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
Score: 0.098
-
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res. 2016 09 01; 76(17):5103-14.
Score: 0.091
-
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Jan; 25(1):193-200.
Score: 0.089
-
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
Score: 0.087
-
Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Mol Cancer. 2015 Feb 03; 14:29.
Score: 0.084
-
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol. 2014 Apr 20; 32(12):1249-55.
Score: 0.079
-
Genetic epidemiology of epithelial ovarian cancer. Cancer. 1993 Jan 15; 71(2 Suppl):566-72.
Score: 0.073
-
Age at onset for familial epithelial ovarian cancer. JAMA. 1992 Oct 14; 268(14):1896-9.
Score: 0.072
-
Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2.
Score: 0.064
-
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
Score: 0.051
-
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 02; 147(7):441-50.
Score: 0.051
-
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15; 107(12):2745-51.
Score: 0.048
-
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71.
Score: 0.045
-
Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. Int J Cancer. 2017 11 01; 141(9):1794-1802.
Score: 0.025
-
Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J Epidemiol. 2016 06; 45(3):896-908.
Score: 0.023
-
Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2013 Jun; 139(2):571-9.
Score: 0.019
-
Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012 May; 133(1):347-55.
Score: 0.017